Last Updated : October 30, 2024
Details
FilesGeneric Name:
nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0360-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with gemcitabine for the adjuvant treatment of pancreatic cancer.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Submission received | February 12, 2024 |
|---|---|
| Review initiated | February 13, 2024 |
| Expert committee meeting (initial) | July 04, 2024 |
| Draft recommendation posted for stakeholder feedback | August 01, 2024 |
| End of feedback period | August 16, 2024 |
| Final recommendation posted | September 24, 2024 |
| CADTH review report(s) posted | August 21, 2024 |
Files
Last Updated : October 30, 2024